摘要
目的:评价尿多酸肽注射液对135例晚期癌症患者生活质量的影响及临床应用价值。方法:应用欧洲癌症研究与治疗组织推出的生活质量核心量表EORTCQLQ-C30(V3.0)中文版,采用多中心、开放、非随机的方法,对135例晚期癌症患者使用尿多酸肽单药治疗,在治疗前后2,4,6周分别进行1次问卷调查;尿多酸肽注射液深静脉点滴给药,1次/d,连续用药4～8周。结果:尿多酸肽对135例晚期癌症患者EORTCQLQ-C30(V3.0)15项领域中位有效改善率为44.5%;其中原发性肝癌、非小细胞肺癌、结直肠癌、乳腺癌、胃癌、食管癌、脑胶质瘤等的15项领域中位有效改善率分别为52.9%,37.0%,42.9%,50.0%,35.8%,37.5%,33.3%。结论:尿多酸肽可明显改善晚期癌症患者的生活质量,在肿瘤临床治疗中具有一定的应用价值。
AIM:To evaluate the influences of uroaci tides on the qualit y of life(QOL)in 135cases of advanced cancer patie nts and value of clinical applicatio n .METHODS :The quality of patients life were als o questioned and evaluated using the Chinese version of QLQ-C 30developed the European Organiz atio n for Research and Treatment of Cancer(EORTC).This study was designed as a multi-center,non-randomized open clinical study at 12different hosp ital s.Uroacitides was administered as a single agent in a dosage of 300ml throug h the deep vein catheter.The 135patie nts entered into the study were treate d with uroacitides once a day for 4-8we eks.The clinical benefits(KPS,pain ,body,weight,symptoms )and the quality of life were question naire survey in 135patients before and after 2,4,6,8weeks treatments with uroacitides .RESULTS:The median response rate for 15scale s of EORTC QLQ-C 30was 44 .5%among 135patients.The med ians response rates were52.9%,37.0 %,42.1%,50.0%,35.8%,37.5%and 33.3%,re-spectively in the patients with prim ary liver cancer,non-small cell lun g cancer,color ectal cancer,breast c ancer,gastric cancer,esophageal c ancer and brain tumor .Uroacitides can improve the quality of life significantly in advan ced cancer patients and have clinical treatment value.
出处
《中国临床康复》
CSCD
2004年第2期384-385,共2页
Chinese Journal of Clinical Rehabilitation
